Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDLI In Brief

This article was originally published in The Gray Sheet

Executive Summary

OPPS: Proposed rule for the hospital outpatient prospective payment system, including information on new device categories, will be issued "around the fourth of July," CMS Purchasing Policy Group Director Thomas Gustafson tells attendees at the Food and Drug Law Institute's annual meeting held in Washington, D.C. April 16-17. A final rule is on schedule for promulgation by Oct. 1. According to Gustafson, 83 out of 97 device categories are scheduled to sunset and lose their "pass-through" status in January 2003...

You may also be interested in...



Medtronic LifePak DTC Ads May Foreshadow Future Heart Failure Campaign

Medtronic says it will evaluate its LifePak Home Solution automated external defibrillator direct-to-consumer advertising campaign with an eye toward similar promotional efforts for other therapies, such as resynchronization for congestive heart failure

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

UsernamePublicRestriction

Register

MT016441

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel